MSGID: 1:317/3 641bd5e5   
   PID: hpt/lnx 1.9.0-cur 2019-01-08   
   TID: hpt/lnx 1.9.0-cur 2019-01-08   
    Known active ingredient as new drug candidate against mpox    
      
     Date:   
         March 22, 2023   
     Source:   
         Goethe University Frankfurt   
     Summary:   
         Mpox -- previously known as 'monkeypox' -- is currently spreading   
         worldwide. Researchers have now identified a compound that could   
         help fight the disease.   
      
      
         Facebook Twitter Pinterest LinkedIN Email   
   FULL STORY   
   ==========================================================================   
   Mpox -- previously known as "monkeypox" -- is currently spreading   
   worldwide. An international research team from Goethe University and   
   the University of Kent has now identified a compound that could help   
   fight the disease. Their study has been published in the Journal of   
   Medical Virology.   
      
      
   ==========================================================================   
   Nitroxoline is the name of the new drug candidate that could potentially   
   be used to treat mpox. It was identified by scientists at Goethe   
   University and the University of Kent as part of a multi-site study. The   
   results of their research will now allow clinical trials to begin soon.   
      
   The current mpox outbreak is the first of this size to occur outside   
   of Africa and also the first mpox outbreak caused by human-to-human   
   transmission. People with immunodeficiencies are particularly at risk   
   from the disease. Although antiviral agents have already been shown   
   to inhibit the replication of the mpox virus in experimental models,   
   the efficacy of these substances has not yet been confirmed in humans   
   and some may have significant side effects. In addition, there are   
   insufficient stocks to treat all mpox patients. Moreover, resistance   
   formation against tecovirimat, the most promising mpox drug candidate   
   to date, has already been reported.   
      
   In the present study, the international team led by Professor Jindrich   
   Cinatl (of Goethe University Frankfurt and the Dr. Petra Joh-Research   
   Institute) and Professor Martin Michaelis (School of Biosciences,   
   University of Kent) has identified nitroxoline, a well-tolerated   
   antibiotic, as a potential treatment alternative for the mpox virus   
   based on experiments using cell culture and skin explant models.   
      
   Nitroxoline is also effective against a tecovirimat-resistant strain of   
   the mpox virus, as well as other bacterial and viral pathogens that are   
   frequently co-transmitted with mpox viruses, meaning it simultaneously   
   suppresses multiple pathogens that are often involved in severe courses   
   of mpox. Since nitroxoline is a well-tolerated antibiotic that has long   
   been used to treat humans, it can be tested directly against mpox in   
   clinical trials.   
      
   "The emergence of resistant virus strains is a cause of great concern,"   
   says Professor Jindrich Cinatl of Goethe University and the Dr. Petra   
   Joh-Research Institute. "It is very reassuring that nitroxoline is   
   effective against a tecovirimat-resistant virus."  Professor Martin   
   Michaelis of the University of Kent adds: "The more different drugs become   
   available to treat viral diseases, the better. We hope that nitroxoline   
   will turn out to be an effective treatment for mpox patients."   
       * RELATED_TOPICS   
             o Health_&_Medicine   
                   # Pharmacology # Viruses # Infectious_Diseases #   
                   HIV_and_AIDS   
             o Plants_&_Animals   
                   # Virology # Microbes_and_More # Biology # Bacteria   
       * RELATED_TERMS   
             o Huntington's_disease o Prion o Mumps o Stem_cell_treatments   
             o Alzheimer's_disease o Neoteny o Air_pollution o   
             Legionnaires'_disease   
      
   ==========================================================================   
   Story Source: Materials provided by Goethe_University_Frankfurt. Note:   
   Content may be edited for style and length.   
      
      
   ==========================================================================   
   Journal Reference:   
      1. Denisa Bojkova, Nadja Zo"ller, Manuela Tietgen, Katja Steinhorst,   
      Marco   
         Bechtel, Tamara Rothenburger, Joshua D. Kandler, Julia Schneider,   
         Victor M. Corman, Sandra Ciesek, Holger F. Rabenau, Mark N. Wass,   
         Stefan Kippenberger, Stephan Go"ttig, Martin Michaelis, Jindrich   
         Cinatl.   
      
         Repurposing of the antibiotic nitroxoline for the treatment of mpox.   
      
         Journal of Medical Virology, 2023; 95 (3) DOI: 10.1002/jmv.28652   
   ==========================================================================   
      
   Link to news story:   
   https://www.sciencedaily.com/releases/2023/03/230322190939.htm   
      
   --- up 1 year, 3 weeks, 2 days, 10 hours, 50 minutes   
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)   
   SEEN-BY: 15/0 106/201 114/705 123/120 153/7715 226/30 227/114 229/110   
   SEEN-BY: 229/111 112 113 307 317 400 426 428 470 664 700 292/854 298/25   
   SEEN-BY: 305/3 317/3 320/219 396/45   
   PATH: 317/3 229/426